PAR-25-211-Full-Announcement.html

This document is a Notice of Funding Opportunity (NOFO) for the federal grant opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)". The purpose of this NOFO is to support innovative mechanistic research to accelerate precision probiotic interventions using a two-phase R61/R33 award mechanism. The R61 phase, up to 2 years, will identify unique host biological patterns that correlate with heterogeneity in probiotic clinical effects. The subsequent R33 phase will assess the ability of the identified patterns to improve probiotic responsiveness in animal models or human subjects. The combined R61/R33 award should not exceed 5 years. Eligible applicant types include for-profit organizations, higher education institutions, nonprofits, and government entities. This NOFO is associated with several NIH research programs, including those focused on women's health, cancer, oral diseases, complementary health, and aging research.